Growth in the primary cells market is
mainly driven by factors such as increasing cancer research, the advantages of
primary human cells over cell lines, the increasing demand for monoclonal
antibodies, rapid growth in the biotechnology & biopharmaceutical
industries, and growing focus on personalized medicine. Biomedical research
using primary cells in 3D cultures is also expected to provide a wide range of
growth opportunities for players in the market. On the other hand, concerns
regarding primary cell culture contamination are expected to limit market
growth to a certain extent in the coming years.
Download PDF Brochure: @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960
The global primary cells market size is
projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a
CAGR of 10.7% during the forecast period.
The human primary cells segment
accounted for the largest share of the primary cells market, by origin segment,
in 2019
Based on origin, the primary cells market
is segmented into human and animal primary cells. The human primary cells
segment accounted for the largest share in the primary cells market in 2019.
The growing application areas of human stem cells and the rising incidence of
cancer are the major factors driving the growth of this segment.
Hepatocytes segment to register the
highest growth rate during the forecast period
Based on type, the primary cells market is
segmented into hematopoietic cells, dermatocytes, gastrointestinal cells,
hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and
other primary cells. In 2019, the hepatocytes segment accounted for the highest
growth rate. This can be attributed to the increasing incidence of liver cancer
& pediatric liver diseases across the globe, increasing research funding by
key pharma players, and the emergence of new companies dedicated to liver
therapeutics research.
The life science research companies
segment accounted for the largest share of the primary cells market, by end
user segment, in 2019
Based on end-users, the primary cells
market is segmented into life science research companies and research
institutes. In 2019, the life science research companies segment for the
largest share in the primary cells market. Increasing cancer research in life
science research companies, the increasing number of R&D facilities, high
adoption of primary cells in cell-based experiments, and the increasing
investments of companies in cell-based research are the major factors driving
the growth of this segment.
North America is the largest regional
market for primary cells market
The primary cells market is segmented into
four major regions, namely, North America, Europe, Asia Pacific, and the Rest
of the World (RoW). In 2019, North America accounted for the largest share in
the primary cells market. The growth in the North American primary cells market
can be attributed to increasing funding for cancer research, growing life
science research sector, expansion of the healthcare sector, and the high
adoption of stem cell therapy & cell immunotherapies for the treatment of
cancer and chronic diseases.
The major players operating in this market
are Thermo Fisher Scientific, Inc. (US),
Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell
GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL
Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American
Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells
Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell
Research Laboratories, Inc. (US), PPA Research Group, Inc. (US), Creative
Bioarray (US), BPS Bioscience, Inc. (US), Epithelix Sàrl (Switzerland),
ReachBio LLC (US), AcceGen (US), Sekisui XenoTech, LLC (US), and Biopredic
International (France).
Thermo Fisher Scientific accounted for the largest share of the primary cells market in
2019. The company maintains its leading position in the primary cells market
due to its well-established product portfolio. The company adopted partnerships
and expansions as key strategies to strengthen its position as well as expand
its product portfolio. Thermo Fisher Scientific will be investing more than USD
475 million in new capabilities at its St. Louis site (Missouri, US) to expand
its biologics development & manufacturing, cell & gene therapy, and
drug product development capacity. Such developments have helped the company
enhance its visibility in the primary cells market.